(Morning News) US Pfizu is expectedThe price of Pfizer-Biontech is increased to $ 110 to $ 130 per dose (about S $ 157 to S $ 1,185).
Reuters reported that Angela Lukin, a senior manager of Pfizer, revealed at the call meeting with analysts on Thursday (October 20) that Pfizer and the US government's current coronary vaccine procurement plan arrivedAfter the period, the price of vaccine is expected to be raised.
However, Lu Jin said that people with private insurance or government payment insurance will be able to obtain this vaccine for free.
The US government currently vaccinate the Pfizer-Biontech vaccine for free, and the cost paid by Pfizer and German company Biontech SE is about $ 30 per vacor.
The public health emergency status of crown diseases in the United States ended in 2023. The relevant costs are expected to be responsible for private insurance companies.It is not clear what people who have no health insurance can get the vaccine.
Pfizer is expected to be equivalent to the scale of the crown vaccine market each year as the scale of the adult influenza vaccine market. However, according to the vaccine provided so far, the pediatric crown vaccine market will take longer to be established.
Reuters reported on the 20th that due to weak crown vaccine demand, Wall Street is expected to rise.
Lu Jin believes that the purchase of the crown vaccine is the fastest to wait until the first quarter of 2023 will be transferred to the private industry. This depends on the end of the government's contract supply.
